DYOR more then 7 hours
The trial was designed to assess the safety and antiviral activity of three month’s dosing of BIT225 in combination with antiretroviral drugs in treatment-naïve HIV-positive subjects. This was a double-blind, placebo-controlled study undertaken at trial sites in Thailand. A total of 27 HIV-infected subjects, who had not previously taken any antiretroviral drugs, took once daily doses of 200 mg BIT225 or placebo for 12 weeks in combination with antiretroviral drugs. At the end of 12 weeks, all continued to take antiretroviral drugs as per standard protocols. A smaller cohort of 9 subjects took once daily doses of 100 mg BIT225 or placebo; this cohort was set up for detailed pharmacokinetic profiling of the BIT225 and its interactions with antiretroviral drugs.
Add to My Watchlist
What is My Watchlist?
